News for BioRestorative Therapies Inc (BRTXQ)

MELVILLE, N.Y., June 18, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (”œBioRestorative”, ”œBRTX” or the ”œCompany”) (BRTX), a clinical st

MELVILLE, N.Y., June 17, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (”œBioRestorative”, ”œBRTX” or the ”œCompany”) (BRTX), a clinical st

BioRestorative Therapies, symbolized by the ticker BRTX, recently revealed that its Board of Directors has approved a stock buyback initiative. This program all

**media[654003]**

BioRestorative Therapies (BRTX) has appointed Sandy Lipkins, effective June 9, 2025, to spearhead technology commercialization and business growth. Lipkins' res

MELVILLE, N.Y., June 10, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (”œBioRestorative”, ”œBRTX” or the ”œCompany”) (BRTX), a clinical st

BioRestorative Therapies (BRTX) to reveal new Phase 2 data for BRTX-100 at ISSCR 2025 in Hong Kong. Preliminary results from 30 patients highlight potential

Revenue: $25,000 for Q1 2025, compared to $35,000 in Q1 2024.Deferred Revenue: $150,000 in Q1 2025, compared to nil in Q1 2024.Loss from Operations: $4.8 milli

May 14, 2025 / 08:30PM GMTOperator Good afternoon, everyone, and welcome to the BioRestorative Therapies first-quarter 2025 investor call. (Operator Instruction

BioRestorative Therapies, Inc. (NASDAQ:BRTX) Q1 2025 Earnings Call May 14, 2025 4:30 PM ETCompany ParticipantsStephen Kilmer - Investor RelationsLance...

BioRestorative Therapies (NASDAQ:BRTX) to release Q1 2025 financial results post-market on May 14, 2025. The company will hold a conference call at 4:30 p.m

**media[619723]**

BioRestorative Therapies, Inc. (NASDAQ:BRTX) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ETCompany ParticipantsStephen Kilmer – Investor...

MELVILLE, N.Y., March 27, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (”œBioRestorative”, ”œBRTX” or the ”œCompany”) (BRTX), a regenerati

MELVILLE, N.Y., March 20, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (”œBioRestorative”, ”œBRTX” or the ”œCompany”) (BRTX), a clinical s

**media[572507]**

”“ BRTX-100 is the first and only stem cell product candidate cleared to be evaluated in the cervical degenerative disc disease setting ”“ ”“ IND clearance

MELVILLE, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (”œBioRestorative”, ”œBRTX” or the ”œCompany”) (BRTX), a clinical st

**media[551619]**